CNS tumours

343MO - Clinical features and DNA methylation patterns in long- and short-term survivors of WHO grade II-III glioma

Maximilian J. Mair, et al.


Our data indicate that DNA methylation profiling identifies IDH-mutated LGG with unfavorable prognosis. Further studies are needed to elucidate the pathobiology and optimal treatment of these high-risk LGG.


344MO - Experience of GEINO (Spanish cooperative group for research in neuro-oncology) oncologists in the management of adult medulloblastoma

Maria Vieito Villar, et al.


Significant heterogeneity is present in the management of adult MB in Spain. Although treatment in MB should be individualized and treatment outcomes are in line with published series, differences in treatment schemas and availability of molecular diagnostic tools highlight the importance of collaborative groups to standardize management.


345MO - Treatment associated changes in the inflammatory microenvironment composition of brain metastases

Ariane Steindl, et al.


Our data indicate an immunosuppressive effect of radiotherapy on BM, as evidenced by decreased T cell infiltration in radiated versus non-radiated BM specimens. Future clinical studies should focus on the optimal timely sequencing of immune modulating therapies and radiotherapy.


346MO - Safety of idroxioleic acid in combination with standard of care (temozolomide and/or radiation therapy) in newly diagnosed glioblastoma patients: A phase Ib trial

Carme Balaña, et al.


Addition of 12 g daily of 2-OHOA to standard of care (RT/TMZ) in newly diagnosed GBM patients was generally well tolerated, offered a favourable safety profile (no 2-OHOA-related serious or high-grade AEs), and it is the recommended dose of 2-OHOA for phase III trials.


347MO - 5-Aminolevulinic acid sonodynamic therapy in recurrent glioblastoma: A first-in-human phase 0/1 clinical trial

Nader Sanai, et al.


This initial, first-in-human experience with a new therapeutic modality for recurrent glioblastoma indicates that 5-ALA SDT is well-tolerated and safe at 200J. Sonodynamic therapy leads to targeted oxidative stress and accompanying cell death in human glioblastoma tissue.